 we report results for the second quarter of fiscal 2017 and discuss our outlook for the balance of the year. 
 our net sales were $125.6 million, a decrease of 4.5% from the second quarter of fiscal 2016. 
 our gross profit was $30.8 million, a decrease of $14.1 million compared to the second quarter of 2016. our gross margin was 24.5% compared to 27.2% in the prior year period. 
 our gross profit in the human health segment fell $16.9 million, a 22% decrease from the prior year period. 
 gross profit in the pharmaceutical ingredient segment was $36.8 million, an increase of 7.4% versus the second quarter of 2016, largely on the strong sales gain abroad and our pharma intermediate business. 
 gross profit in the pharma ingredient segment rose by 2.6% to $8.2 million versus $8 million in the prior year period and our gross margin increased 280 basis points to 23.7% which was driven by the more profitable mix of sales of our agricultural protection products. 
 the second quarter results were impacted by supply interruptions on two of our commercial products at Rising as we previously noted during our first